Concepedia

Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular β-decitabine nucleotides and genomic DNA incorporated β-decitabine and 5-methyl-2′-deoxycytidine

Jeroen Roosendaal, Hilde Rosing, Luc Lucas, Aram Oganesian, Jan H.M. Schellens, Jos H. Beijnen

Journal of Pharmaceutical and Biomedical Analysis · 2018 · 10 citations · 13 references

DOIFull text

Open access

Concepts

References

13

Decitabine improves patient outcomes in myelodysplastic syndromes

Hagop M. Kantarjian, Jean‐Pierre J. Issa, C Rosenfeld et al. · Cancer · 2006 · 1.5K citations

, , +14

Concise Drug Review: Azacitidine and Decitabine

Ellen J. B. Derissen, Jos H. Beijnen, Jan H.M. Schellens · The Oncologist · 2013 · 294 citations · Full text

, , +14

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Jean‐Pierre J. Issa, Gail J. Roboz, David A. Rizzieri et al. · The Lancet Oncology · 2015 · 281 citations · Full text

, , +13

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy

Metin Karahoca, Richard L. Momparler · Clinical Epigenetics · 2013 · 209 citations · Full text

, , +17

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses

Ron J. Keizer, Robert S. Jansen, Hilde Rosing et al. · Pharmacology Research & Perspectives · 2015 · 196 citations · Full text

, , +16